Claims for Patent: 8,338,385

Summary for Patent: 8,338,385

Title:	Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
Abstract:	The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.
Inventor(s):	Kim; Jong-Mook (Seoul, KR), Hahn; Woong (Gyeonggi-do, KR)
Assignee:	ViroMed Co., Ltd. (KR)
Application Number:	12/908,765
Patent Claims:	1. A method of treating an ischemic limb disease in a subject comprising intramuscularly administering to the ischemic limb of said subject a hybrid Hepatocyte Growth Factor (HGF) construct comprising: (a) a first cDNA which has the same sequence as exons 1-4 of the human HGF gene wherein said exons 1-4 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said first cDNA, (b) a polynucleotide that has the same sequence as intron 4 of a HGF gene or a fragment thereof, and (c) a second cDNA which has the same sequence as exons 5-18 of the human HGF gene wherein said exons 5-18 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said second cDNA, wherein (b) is located between (a) and (c) and the HGF construct simultaneously encodes two heterotypes of human HGF; wherein said administration treats the ischemic limb disease in said subject. 2. The method of claim 1, wherein the polynucleotide of (b) has the same sequence as the full intron 4 of the human HGF gene. 3. The method of claim 2, wherein said hybrid HGF construct comprises a nucleotide sequence comprising SEQ ID NO: 2. 4. The method of claim 1, wherein the polynucleotide of (b) has the same sequence as a fragment of intron 4 of the human HGF gene. 5. The method of claim 4, wherein said hybrid HGF construct comprises SEQ ID NO: 19. 6. The method of claim 4, wherein said hybrid HGF construct comprises SEQ ID NO: 20. 7. The method of claim 4, wherein said hybrid HGF construct comprises SEQ ID NO: 21. 8. The method of claim 1, wherein said hybrid HGF construct is comprised in a vector. 9. The method of claim 8, wherein said vector further comprises one or more sequences for regulating expression, a self-replication sequence, or a secretory signal. 10. The method of claim 8, wherein said vector comprising said HGF construct is selected from the group consisting of: pCK-HGF-X1, pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X4, pCK-HGF-X5, pCK-HGF-X6, pCK-HGF-X7, pCK-HGF-X8, pCP-HGF-X1, pCP-HGF-X2, pCP-HGF-X3, pCP-HGF-X4, pCP-HGF-X5, pCP-HGF-X6, pCP-HGF-X7 and pCP-HGF-X8. 11. The method of claim 1, wherein said hybrid HGF construct is administered by direct injection. 12. A method of treating an ischemic limb disease in a subject comprising intramuscularly administering to the ischemic limb of said subject a hybrid Hepatocyte Growth Factor (HGF) construct comprising a polynucleotide having a nucleotide sequence not less than 90% identical to a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21, wherein the polynucleotide having said nucleotide sequence simultaneously encodes two heterotypes of human HGF, wherein said administration treats the isehernic limb disease in said subject. 13. The method of claim 12, wherein said nucleotide sequence is not less than 95% identical to SEQ ID NO:2. 14. The method of claim 12, wherein said nucleotide sequence is not less than 95% identical to SEQ ID NO: 19. 15. The method of claim 12, wherein said nucleotide sequence is not less than 95% identical to SEQ ID NO: 20. 16. The method of claim 12, wherein said nucleotide sequence is not less than 95% identical to SEQ ID NO: 21.

Details for Patent 8,338,385

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2022-03-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2022-03-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2022-03-20